Lifeline for kids with HIV: free access to key drug
NCT ID NCT03016533
First seen Feb 05, 2026 · Last updated May 13, 2026 · Updated 18 times
Summary
This study offers children and teens with HIV continued access to dolutegravir, a powerful HIV medication, after they finished earlier studies. About 100 participants who tolerated the drug well will receive age-appropriate doses every 12 weeks until the drug is locally approved and available. The goal is to keep their HIV under control without interruption.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Los Angeles, California, 90095, United States
-
GSK Investigational Site
Fort Lauderdale, Florida, 33316, United States
-
GSK Investigational Site
Memphis, Tennessee, 38105-3678, United States
-
GSK Investigational Site
Gaborone, Botswana
-
GSK Investigational Site
Belo Horizonte, 30130-100, Brazil
-
GSK Investigational Site
Nova Iguaçu, 26030-380, Brazil
-
GSK Investigational Site
RibeirAo PretoSP, 14048-900, Brazil
-
GSK Investigational Site
Rio de Janeiro, 21941-612, Brazil
-
GSK Investigational Site
Cape Town, 7505, South Africa
-
GSK Investigational Site
Johannesburg, 2001, South Africa
-
GSK Investigational Site
Soweto, 1862, South Africa
-
GSK Investigational Site
Umlazi, 4066, South Africa
-
GSK Investigational Site
Moshi, 3010, Tanzania
-
GSK Investigational Site
Bangkok, 10700, Thailand
-
GSK Investigational Site
Chiang Mai, 50200, Thailand
-
GSK Investigational Site
Chiang Rai, 57000, Thailand
-
GSK Investigational Site
Harare, Zimbabwe
Conditions
Explore the condition pages connected to this study.